Alnylam Pharmaceuticals, Inc.ALNYNASDAQ
Loading
Book Value/Share Growth AcceleratingAccelerating
Percentile Rank97
Year-over-Year Change
Year-over-year book value per share growth
Latest
235.40%
↑ 665% vs avg
Percentile
P97
Near historical high
Streak
1 qtr
Consecutive growthAccelerating
Average
30.79%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | 235.40% |
| Q3 2025 | -7.92% |
| Q2 2025 | 117.08% |
| Q1 2025 | 70.62% |
| Q4 2024 | 107.36% |
| Q3 2024 | 1139.67% |
| Q2 2024 | 98.61% |
| Q1 2024 | 1.04% |
| Q4 2023 | -32.61% |
| Q3 2023 | 59.54% |
| Q2 2023 | -56.74% |
| Q1 2023 | -62.73% |
| Q4 2022 | -131.84% |
| Q3 2022 | -138.02% |
| Q2 2022 | -56.38% |
| Q1 2022 | -32.02% |
| Q4 2021 | -22.75% |
| Q3 2021 | -12.26% |
| Q2 2021 | -8.40% |
| Q1 2021 | -9.49% |
| Q4 2020 | -16.57% |
| Q3 2020 | -14.00% |
| Q2 2020 | 1.75% |
| Q1 2020 | -7.01% |
| Q4 2019 | -12.92% |
| Q3 2019 | -8.65% |
| Q2 2019 | 10.27% |
| Q1 2019 | 13.93% |
| Q4 2018 | -12.16% |
| Q3 2018 | -9.04% |
| Q2 2018 | -8.13% |
| Q1 2018 | -4.47% |
| Q4 2017 | 59.35% |
| Q3 2017 | -9.54% |
| Q2 2017 | 31.97% |
| Q1 2017 | -9.90% |
| Q4 2016 | -9.47% |
| Q3 2016 | -7.79% |
| Q2 2016 | -7.91% |
| Q1 2016 | -6.43% |